Biomemory

Biomemory is a Synthetic Genomics & Data Storage company founded in 2021 and based in Paris, France. It has raised $23M in total funding, most recently a Series A in 2024.

Biomemory was founded in 2021 in Paris by Erfane Arwani, a computer scientist who serves as CEO, alongside Sorbonne University researchers Stephane Lemaire and Pierre Crozet. The company encodes digital data into synthetic DNA using a petroleum-free enzymatic synthesis process, targeting data-center cold storage with far higher density and durability than tape, and markets a credit-card-format DNA Card. In December 2024 it raised an $18 million Series A led by Credit Mutuel Innovation, and in March 2026 it acquired the assets of failed US rival Catalog Technologies, gaining Catalog's intellectual property and plans for a Boston R&D footprint as it works toward a first commercial DNA-storage product in the second half of 2026.

It is a leading European bet on DNA as a practical archival-storage medium, and its absorption of Catalog's assets made it a consolidator in a nascent data-storage market.

biomemory.com Synthetic Genomics & Data Storage

Franceprivate

At a glance

Total raised

$23M

last round series a

Headcount

11-50

approximate · public range

Headquarters

Paris

France

Founded

2021

5 years active

Status

Private

Synthetic Genomics & Data Storage

Subsector

Funding history

Total raised

$23M

Rounds tracked

Latest stage

Series A

Date	Stage	Amount	Valuation	Lead investors
Dec 10, 2024	Series A	$18M	—	Credit Mutuel Innovation

In the news

Biomemory · last 30 days

Biomemory

At a glance

Funding history

In the news

Leadership

Products

DNA Card

Open roles

Compare Biomemory with